US › Healthcare

ADMA Biologics Inc (ADMA)

US · Healthcare · Biotechnology

$8.91+1.95%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$114.5M

Revenue YoY

-0.3%

Net profit

$45.3M

Profit YoY

+68.5%

EPS

$0.17

EPS estimate

$0.20

Net margin

39.6%

EPS came in at 0.17 against a street estimate of 0.20 — a miss of 15.0%.

Key statistics

Market cap

$1.96B

P/E

12.4

Forward P/E

10.2

P/B

5.02

Book value

$1.68

EPS (TTM)

$0.68

52-week high

$20.46

52-week low

$7.21

50-day MA

$8.49

200-day MA

$13.34

Beta

0.73

Analyst view

Analysts rate ADMA Biologics Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $17.00.

Shareholding

Insiders

1.90%

Institutions

93.70%

Largest institutional holders

Fund	Stake
BlackRock Inc	15.85%
State Street Corp	6.06%
Capital Research Global Investors	4.82%
Vanguard Capital Management, LLC	4.44%
Vanguard Portfolio Management, LLC	3.82%
Nuveen, LLC	2.62%
Geode Capital Management, LLC	2.51%
Citadel Advisors Llc	2.50%

Recent filings & reports

Document	Date
Shareholder vote results · Q2 2026	2026-06-02
Quarterly report · Q1 2026	2026-05-06
Results announced · Q2 2026	2026-05-06
Company announcement · Q2 2026	2026-05-04
Proxy statement · Q2 2026	2026-04-15
Reg FD disclosure · Q1 2026	2026-03-27
Annual report FY2025	2026-02-25
Quarterly report · Q3 2025	2025-11-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ADMA Biologics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.